Related Experiment Video
Updated: Jul 9, 2026

Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
High-yield and cost-effective biosynthesis process for producing antimicrobial peptide AA139
Ying Zhang1, Yapeng Wang1, Jianguang Lu2
1School of Pharmacy, Fudan University, Shanghai, 201203, People's Republic of China; Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, 201203, People's Republic of China.
Abstract:
AA139, a variant of natural antimicrobial peptide (AMP) arenicin-3, displayed potent activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria. Nevertheless, there were currently few reports on the bioprocess of AA139, and the yields were less than 5 mg/L. Additionally, it was difficult and expensive to prepare AA139 through chemical synthesis due to its complex structure. These factors have impeded the further research and following clinical application of AA139. Here, we reported a bioprocess for the preparation of AA139, which was expressed in Escherichia coli (E. coli) BL21 (DE3) intracellularly in a soluble form via SUMO (small ubiquitin-related modifier) fusion technology. Then, recombinant AA139 (rAA139, refer to AA139 obtained by recombinant expression in this study) was obtained through the simplified downstream process, which was rationally designed in accordance with the physicochemical characteristics. Subsequently, the expression level of the interest protein was increased by 54% after optimization of high cell density fermentation (HCDF). Finally, we obtained a yield of 56 mg of rAA139 from 1 L culture with a purity of 98%, which represented the highest reported yield of AA139 to date. Furthermore, various characterizations were conducted to confirm the molecular mass, disulfide bonds, and antimicrobial activity of rAA139.
Insights
This study developed a novel bioprocess for producing AA139, a potent antimicrobial peptide (AMP), overcoming previous yield limitations. The optimized method achieved significantly higher yields of AA139 for potential clinical applications against resistant bacteria.
Area of Science:
- Biotechnology
- Microbiology
- Biochemistry
Background:
- AA139, a potent antimicrobial peptide (AMP) variant, shows activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria.
- Previous production methods for AA139 yielded less than 5 mg/L and were hindered by complex chemical synthesis, limiting research and clinical use.
Purpose of the Study:
- To establish an efficient bioprocess for producing AA139.
- To significantly increase the yield and purity of recombinant AA139 (rAA139) for further investigation and potential clinical applications.
Main Methods:
- AA139 was expressed intracellularly in Escherichia coli (E. coli) BL21 (DE3) using SUMO fusion technology.
- A simplified downstream process was developed based on physicochemical characteristics.
- High cell density fermentation (HCDF) was optimized to enhance protein expression by 54%.
Main Results:
- A yield of 56 mg of rAA139 per liter of culture was achieved with 98% purity, the highest reported to date.
- Characterization confirmed the molecular mass, disulfide bonds, and antimicrobial activity of the produced rAA139.
- The developed bioprocess overcomes previous limitations in AA139 production.
Conclusions:
- The study presents a highly efficient bioprocess for producing recombinant AA139.
- This optimized production method significantly increases yield and purity, facilitating future research and clinical development of AA139 as an antimicrobial agent.
Related Concept Videos
Upstream Processing
Production of Organic Acids
Production of Antibiotics
Production of Pharmaceuticals

